Technical Analysis for BIOC - Biocept, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
0.92 | 6.79% | 0.06 |
BIOC closed up 6.79 percent on Friday, September 13, 2019, on 2.62 times normal volume.
Earnings due: Sep 27
*** please verify all earnings dates ***| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| See historical BIOC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 6.79% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 6.79% | |
| Oversold Stochastic | Weakness | 6.79% | |
| Narrow Range Bar | Range Contraction | 4.58% | |
| Oversold Stochastic | Weakness | 4.58% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Diagnostics & Research
Biocept, Inc., a cancer diagnostics company, is engaged in the development and commercialization of proprietary circulating tumor cell (CTC) and circulating tumor DNA tests. The company's tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. Its tests include OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company sells its products through its sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Medicine Cancer Medical Specialties Clinical Medicine Oncology Tumor Tumors Anatomical Pathology
Medicine Cancer Medical Specialties Clinical Medicine Oncology Tumor Tumors Anatomical Pathology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BIOC news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 3.72 |
| 52 Week Low | 0.66 |
| Average Volume | 445,901 |
| 200-Day Moving Average | 1.1128 |
| 50-Day Moving Average | 0.9781 |
| 20-Day Moving Average | 0.9065 |
| 10-Day Moving Average | 0.875 |
| Average True Range | 0.0451 |
| ADX | 21.4 |
| +DI | 20.092 |
| -DI | 19.8541 |
| Chandelier Exit (Long, 3 ATRs ) | 0.9147 |
| Chandelier Exit (Short, 3 ATRs ) | 0.9653 |
| Upper Bollinger Band | 0.9883 |
| Lower Bollinger Band | 0.8247 |
| Percent B (%b) | 0.58 |
| BandWidth | 18.047435 |
| MACD Line | -0.032 |
| MACD Signal Line | -0.0358 |
| MACD Histogram | 0.0039 |
| Fundamentals | Value |
|---|---|
| Market Cap | 27.84 Million |
| Num Shares | 30.3 Million |
| EPS | -1.06 |
| Price-to-Earnings (P/E) Ratio | -0.87 |
| Price-to-Sales | 5.54 |
| Price-to-Book | 3.79 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.04 | ||||
| Resistance 3 (R3) | 1.03 | 0.99 | 1.02 | ||
| Resistance 2 (R2) | 0.99 | 0.96 | 0.99 | 1.01 | |
| Resistance 1 (R1) | 0.95 | 0.94 | 0.97 | 0.96 | 1.01 |
| Pivot Point | 0.91 | 0.91 | 0.92 | 0.91 | 0.91 |
| Support 1 (S1) | 0.87 | 0.88 | 0.89 | 0.88 | 0.83 |
| Support 2 (S2) | 0.83 | 0.86 | 0.83 | 0.83 | |
| Support 3 (S3) | 0.79 | 0.83 | 0.82 | ||
| Support 4 (S4) | 0.80 |
